Enter assignee name

% Expired Patents = 42.9

EPO Patents = 2

Trademarks = 3

Forward Citations = 70

Loading Chart...

4 inventors (with patents filed for the assignee):

Ross Graham Clark (7 out of 30 patents)

Gillian Clark, Legal Representative (2 out of 2 patents)

George M Bright (1 out of 1 patent)

4. Sam Liao (1 out of 1 patent)

7 patents: Sort by Forward Citations

1. 8440616 - Methods for treatment of insulin-like growth factor-1 deficiency (2013-05-14),

2. 8158582 - Methods for treatment of insulin-like growth factor-1 deficiency (2012-04-17),

3. 8133862 - Methods for treatment of insulin-like growth factor-1 (IGF-1) deficiency (2012-03-13),

4. 8108149 - Method and device for diagnosing and treating insulin-like growth factor deficiency disorders (2012-01-31),

5. 7833964 - Methods of reducing visceral fat by increasing levels of insulin-like growth factor-I (IGF-I) (2010-11-16),

6. 7517530 - Methods for treatment of insulin-like growth factor-1 (IGF-1) deficiency comprising administration of IGF-1 and growth hormone (2009-04-14),

7. 7258864 - Methods for treatment of insulin-like growth factor-1 (IGF-1) deficiency (2007-08-21),

Tercica, Inc. is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for endocrine diseases. The company's primary product is Increlex, a treatment for children with severe primary insulin-like growth factor-1 deficiency. Tercica is committed to improving the quality of life for patients with rare endocrine disorders through cutting-edge research and development.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

7 Patents

#126 in South San Francisco, CA

#9,491 in California

#39,879 in US

South San Francisco, CA, United States of America

Tercica, Inc.

Forward Citations = 70

4 inventors:

Ross Graham Clark (7 out of 30 patents)

Gillian Clark, Legal Representative (2 out of 2 patents)

George M Bright (1 out of 1 patent)

4. Sam Liao (1 out of 1 patent)

Please report any incorrect information to [email protected]